List of Excipients in Branded Drug HETLIOZ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Vanda Pharmaceuticals Inc	HETLIOZ	tasimelteon	43068-220	ANHYDROUS LACTOSE
Vanda Pharmaceuticals Inc	HETLIOZ	tasimelteon	43068-220	CELLULOSE, MICROCRYSTALLINE
Vanda Pharmaceuticals Inc	HETLIOZ	tasimelteon	43068-220	CROSCARMELLOSE SODIUM
Vanda Pharmaceuticals Inc	HETLIOZ	tasimelteon	43068-220	FD&C BLUE NO. 1
Vanda Pharmaceuticals Inc	HETLIOZ	tasimelteon	43068-220	FD&C RED NO. 3
Vanda Pharmaceuticals Inc	HETLIOZ	tasimelteon	43068-220	FD&C YELLOW NO. 6
Vanda Pharmaceuticals Inc	HETLIOZ	tasimelteon	43068-220	GELATIN

HETLIOZ Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

HETLIOZ, marketed by Vanda Pharmaceuticals as tasimelteon, has two dosage forms: a 20 mg capsule for Non-24-Hour Sleep-Wake Disorder and HETLIOZ LQ, a 4 mg/mL oral suspension for nighttime sleep disturbances in children with Smith-Magenis syndrome. The strongest excipient opportunities are pediatric palatability, dose-flexible liquid delivery, improved suspension stability, and differentiated formulations that reduce administration errors. The largest commercial constraint is the small treated population, not active-ingredient manufacturing complexity.

What dosage forms and excipients are used in HETLIOZ?

HETLIOZ is an orally administered melatonin-receptor agonist. The capsule contains 20 mg of tasimelteon. HETLIOZ LQ contains 4 mg/mL and is intended for pediatric administration under a weight-based dosing regimen.

HETLIOZ capsule composition

The FDA prescribing information identifies the capsule formulation as containing the following inactive ingredients:

Component	Primary formulation function
Lactose monohydrate	Diluent and bulking agent
Microcrystalline cellulose	Filler, dry-binder, and compactability aid
Starch	Filler and disintegration support
Magnesium stearate	Lubricant
Talc	Processing aid and anti-adherent
Gelatin	Capsule shell
Titanium dioxide	Opacifier and colorant
Yellow iron oxide	Colorant

The capsule formulation is conventional and does not appear to rely on a complex modified-release system, lipid carrier, or proprietary nanoparticle platform. Its commercial value is linked primarily to the tasimelteon product, the regulatory record, dosing information, and disease-specific method-of-use protection rather than an unusually complex excipient system.

HETLIOZ LQ oral suspension composition

HETLIOZ LQ uses a liquid vehicle designed for pediatric dosing. The labeled excipient system includes:

Component	Primary formulation function
Glycerin	Humectant, cosolvent, and mouthfeel modifier
Sodium benzoate	Preservative
Sucralose	Sweetener
Xanthan gum	Suspending and viscosity-building agent
Citric acid monohydrate	Acidulant and pH modifier
Sodium citrate dihydrate	Buffer
Flavoring components	Palatability improvement

The suspension platform addresses a different commercial need from the capsule. It supports children who cannot swallow capsules and permits dosing based on body weight. The formulation must maintain uniformity during storage and after shaking, provide consistent withdrawal through the dosing device, and remain acceptable to children and caregivers.

What excipient strategy is most important for HETLIOZ?

The central strategy is to preserve tasimelteon exposure while improving administration. Tasimelteon is metabolized primarily through CYP1A2, with additional involvement from CYP3A4. The label warns against strong CYP1A2 inhibitors, such as fluvoxamine, and strong CYP3A4 inducers, such as rifampin. Excipient changes that alter dissolution, absorption rate, or gastrointestinal transit could complicate an already interaction-sensitive product.

Capsule strategy

For the capsule, commercially realistic improvements include:

• Lower variability in powder filling.
• Reduced capsule-to-capsule weight variation.
• Improved disintegration after storage.
• Replacement of lactose for patients with excipient sensitivities.
• Reduced dependence on gelatin for vegetarian or religious-use markets.
• Color and imprint changes that improve product identification.
• Packaging that limits moisture exposure and medication errors.

A lactose-free capsule could create a niche differentiation opportunity, but the clinical value would be limited unless lactose intolerance or excipient sensitivity is documented as a meaningful barrier to use. A hydroxypropyl methylcellulose capsule could expand acceptability among vegetarian patients, but it would require compatibility and stability work.

Changing the filler or lubricant system could affect powder flow, content uniformity, dissolution, and scale-up performance. A manufacturer seeking a generic or follow-on product would need to demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway. A simple excipient substitution would not eliminate the need to manage formulation-specific regulatory risk.

Liquid strategy

The liquid formulation presents greater commercial opportunity because pediatric adherence depends heavily on taste, texture, dose measurement, and caregiver usability.

The current vehicle uses xanthan gum to suspend tasimelteon and a citrate buffer to control pH. Potential development directions include:

• Lower-viscosity suspensions that withdraw more easily from oral syringes.
• Improved redispersibility after prolonged storage.
• Reduced foaming during shaking.
• More persistent flavor masking.
• Unit-dose sachets or premeasured oral syringes.
• A ready-to-use solution, if solubility and chemical stability permit.
• A powder-for-reconstitution presentation for improved shipping stability.
• Preservative-reduced or preservative-free packaging.
• Smaller bottles that reduce pediatric medication waste.

A true solution would offer the simplest dosing experience, but it would require sufficient tasimelteon solubility and chemical stability across the intended pH range. If those requirements cannot be met without a high cosolvent or surfactant burden, a suspension remains more practical.

A powder-for-reconstitution product could reduce water activity during distribution and improve shelf-life. Its disadvantages include reconstitution errors, a second preparation step, and the need to validate final concentration after reconstitution. A dual-chamber bottle or pharmacy-reconstituted product could reduce some risks but would increase packaging cost.

What formulation patents protect HETLIOZ?

Publicly available product information shows that HETLIOZ has regulatory protection associated with tasimelteon, its approved uses, and product-specific regulatory listings. The exact live patent set must be determined from the current FDA Orange Book and the USPTO patent records because patent term adjustments, terminal disclaimers, pediatric extensions, and litigation outcomes can change effective dates.

Patent categories relevant to HETLIOZ

Patent category	Commercial relevance
Active-ingredient or compound patents	Can block manufacture of tasimelteon itself
Composition or formulation patents	May cover capsule or liquid formulation characteristics
Method-of-use patents	May protect treatment of Non-24 or Smith-Magenis syndrome
Pediatric-use protection	Can delay or limit generic labeling for a protected pediatric indication
Manufacturing patents	May create process barriers if a specific route or impurity-control method is required
Regulatory exclusivity	Can restrict reliance on the reference product for a defined period

For a formulation competitor, the most important question is not whether HETLIOZ contains common excipients. It is whether an issued claim covers a specific combination, concentration range, pH, suspension property, delivery device, or method of administration. Common excipients generally do not create meaningful freedom-to-operate by themselves, but a combination claim can still be relevant if it ties the excipients to a functional limitation.

What is the FDA regulatory status of HETLIOZ?

HETLIOZ capsules were approved by the FDA for Non-24-Hour Sleep-Wake Disorder in totally blind adults. HETLIOZ LQ was later approved for nighttime sleep disturbances in children with Smith-Magenis syndrome. The two products have different clinical use cases and should be treated as separate formulation and market-access assets.

Product	Active ingredient	Strength	Dosage form	FDA indication
HETLIOZ	Tasimelteon	20 mg	Capsule	Non-24-Hour Sleep-Wake Disorder in totally blind adults
HETLIOZ LQ	Tasimelteon	4 mg/mL	Oral suspension	Nighttime sleep disturbances in pediatric patients with Smith-Magenis syndrome

The liquid product is particularly important from a regulatory strategy perspective. A competitor cannot assume that approval of a capsule automatically provides a commercially viable substitute for the pediatric suspension. The formulation, measuring device, taste profile, dosing instructions, and pediatric indication all affect substitutability.

When does HETLIOZ lose exclusivity?

HETLIOZ exclusivity depends on several separate events:

1. Expiration of applicable patents.
2. Expiration of FDA regulatory exclusivity.
3. Approval of an ANDA or 505(b)(2) application.
4. Resolution of any Paragraph IV litigation.
5. Whether a competitor receives approval for the same indications and dosage forms.

The earliest practical generic-entry date may differ by product. A capsule competitor could target the 20 mg dosage form without reproducing the liquid formulation. A pediatric liquid competitor would face a more complex development and labeling strategy.

Orange Book status

The relevant reference products are listed in FDA approval records for HETLIOZ and HETLIOZ LQ. Orange Book listings should be evaluated separately for:

• Listed patents.
• Patent expiration dates.
• Use codes.
• Pediatric exclusivity.
• Any litigation certification history.
• Whether listed patents cover the capsule, suspension, indication, or a combination of these.

A Paragraph IV certification against an Orange Book-listed patent could trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework. A Paragraph III certification would defer approval until patent expiration. A Section viii statement could allow a generic to omit a patented indication if the remaining labeling supports approval.

What generic entry risks exist for HETLIOZ?

Capsule generic risk

The capsule is the more straightforward target. A generic developer could pursue an ANDA if the reference product, dosage form, strength, route, and indication are sufficiently aligned. The main development issues would be:

• Bioequivalence.
• Dissolution matching.
• Capsule fill uniformity.
• Stability.
• Control of degradation products.
• Patent certification and labeling carve-outs.

The use of conventional excipients lowers manufacturing complexity. It also reduces the opportunity to block entry through manufacturing difficulty. A capsule generic could therefore create price pressure if the principal blocking patents and exclusivity periods no longer prevent approval.

Liquid generic risk

The suspension presents higher technical and commercial barriers. A generic applicant must manage:

• Particle-size distribution.
• Sedimentation rate.
• Redispersibility.
• Assay uniformity throughout the bottle.
• Preservative effectiveness.
• Microbial limits.
• Viscosity.
• Dose withdrawal accuracy.
• Taste and caregiver acceptability.
• Compatibility with the oral syringe.

The FDA may accept a formulation that is not organoleptically identical, but poor taste or difficult dosing can materially reduce substitution and adherence. This creates an opportunity for a differentiated 505(b)(2) product even if an ANDA becomes available.

What commercial opportunities exist for HETLIOZ excipient innovation?

Pediatric adherence products

The most defensible opportunity is a pediatric product that improves administration without changing the pharmacologic profile. Potential assets include:

• A low-viscosity, fast-redispersing suspension.
• A better taste-masked product.
• A premeasured oral-syringe presentation.
• A unit-dose liquid for school or caregiver administration.
• A formulation with reduced dosing residue on the bottle.
• A product with improved stability after opening.

These improvements can support lifecycle management, but the commercial return depends on reimbursement and the size of the Smith-Magenis syndrome population.

Specialty pharmacy and caregiver packaging

HETLIOZ products are suited to specialty-pharmacy distribution because treatment is directed at rare circadian and neurodevelopmental disorders. Packaging can create value through:

• Calendar-based dose tracking.
• Child-resistant but caregiver-friendly closures.
• Integrated oral syringes.
• Tamper evidence.
• Temperature and shipment stability.
• Refill reminders.
• Separate packaging for travel and school use.

Packaging patents and device claims may provide stronger differentiation than routine excipient changes.

Lactose-free and vegetarian capsules

A lactose-free capsule or hypromellose shell could address a defined patient preference or tolerability segment. These changes are unlikely to support broad premium pricing by themselves, but they could help a specialty manufacturer create a differentiated product after core exclusivity declines.

Compounded and hospital-use opportunities

Compounding pharmacies may seek a liquid alternative when commercial suspension access is limited. A validated commercial suspension could compete by offering consistent concentration, preservative control, stability data, and a supplied dosing device. Hospital and institutional buyers may value reduced preparation time and fewer dosing errors more than small differences in acquisition price.

How strong is the HETLIOZ formulation estate?

The formulation estate appears strategically stronger for the pediatric suspension than for the conventional capsule, based on technical complexity rather than a conclusion about any particular patent claim.

Dimension	Capsule	Oral suspension
Excipient complexity	Low to moderate	Moderate
Manufacturing difficulty	Moderate	Higher
Bioequivalence risk	Standard oral-product risk	Higher formulation and device risk
Palatability sensitivity	Low	High
Dosing-device dependence	Low	High
Generic substitution risk	Higher after patent expiry	More dependent on product quality
Lifecycle-management opportunity	Moderate	High
Manufacturing IP potential	Limited	Greater

The liquid product can support stronger commercial differentiation through taste, physical stability, packaging, and dosing-device integration. Those advantages may persist after patent expiry because caregivers and prescribers can prefer a product that reduces administration problems.

Which companies are challenging HETLIOZ?

Public market information identifies Vanda Pharmaceuticals as the originator and commercial sponsor of HETLIOZ. The competitive threat is more likely to come from generic or 505(b)(2) applicants than from a direct branded competitor with the same tasimelteon formulation.

The relevant competitive groups are:

• ANDA applicants targeting the 20 mg capsule.
• 505(b)(2) applicants developing alternative tasimelteon liquids.
• Compounding pharmacies supplying extemporaneous liquid preparations.
• Sleep and circadian-rhythm therapies that compete for prescribing budgets.
• Products used in related pediatric sleep disorders, even when they do not share tasimelteon’s mechanism.

Publicly disclosed competitor identity, Paragraph IV filings, settlements, and litigation should be verified against FDA, PACER, Orange Book, and company filings before investment or licensing decisions.

What licensing opportunities exist for HETLIOZ excipients?

Licensing opportunities are strongest in four areas:

1. Pediatric taste-masking systems with evidence in acidic or buffered suspensions.
2. Suspension platforms that improve redispersibility and dose uniformity.
3. Oral dosing devices that reduce withdrawal error.
4. Packaging systems that improve in-use stability and caregiver compliance.

A prospective licensor should seek claims covering measurable performance, such as suspension uniformity, sedimentation behavior, dissolution, taste-masking performance, or dosing accuracy. A generic claim to "a liquid formulation containing tasimelteon and an excipient" is less likely to provide durable commercial leverage than a claim tied to defined concentration ranges and functional outcomes.

What revenue exposure does HETLIOZ face from generic entry?

Revenue exposure depends on the product mix. Capsule sales are more exposed to conventional generic competition because the dosage form is easier to reproduce. HETLIOZ LQ may retain a higher net price if the pediatric population values palatability, dosing convenience, and reliable supply.

A simplified exposure framework is:

Event	Likely commercial effect
Capsule patent expiry without liquid competition	Moderate to high capsule price pressure
Capsule ANDA approval with pediatric carve-out	Capsule erosion, liquid protection largely preserved
Liquid 505(b)(2) approval	Greater branded and pediatric pricing pressure
Improved branded liquid launch	Potential retention of pediatric share
Supply disruption or discontinuation	Opportunity for alternate manufacturers and compounders
Settlement allowing delayed generic entry	Predictable but deferred erosion

Vanda’s public filings should be used to quantify product revenue, gross margin, payer concentration, and dependence on HETLIOZ. Revenue analysis should separate capsule and liquid sales because their substitution dynamics differ. (Vanda Pharmaceuticals, Inc., 2023)

Key Takeaways

• HETLIOZ uses a conventional capsule excipient system and a more strategically important pediatric suspension system.
• The principal excipient opportunity is HETLIOZ LQ, where taste, viscosity, suspension stability, and dose measurement affect adherence.
• A lactose-free or vegetarian capsule is a niche lifecycle option, not a major platform opportunity.
• Liquid formulation and dosing-device claims may provide more durable differentiation than routine filler or lubricant changes.
• Capsule generic entry is likely to be technically simpler than liquid competition once applicable patents and exclusivities expire.
• Orange Book patents, use codes, Paragraph IV certifications, and litigation outcomes must be reviewed at the product level.
• Commercial value is concentrated in pediatric usability, specialty distribution, reliable supply, and formulation consistency.

FAQs About HETLIOZ Excipient and Generic Strategy

Can tasimelteon be formulated as a liquid solution instead of a suspension?

Potentially, but the feasibility depends on tasimelteon solubility, pH stability, taste, preservative requirements, and the level of cosolvent or surfactant needed. A stable solution could simplify dosing but would require substantial formulation and stability validation.

Is HETLIOZ LQ interchangeable with HETLIOZ capsules?

No. The products have different concentrations, dosage forms, administration requirements, and approved patient populations. Substitution depends on the prescription, indication, dose, and applicable regulatory standards.

Could a generic use different excipients from HETLIOZ?

Yes. An ANDA applicant can use different inactive ingredients if the product meets applicable pharmaceutical-equivalence, bioequivalence, safety, stability, and labeling requirements. The applicant must also address any listed patents and regulatory exclusivity.

What is the most valuable excipient technology for pediatric tasimelteon?

A taste-masking and suspension-stability platform integrated with an accurate oral dosing device is likely to have the highest commercial value. The technology should improve measurable attributes such as dose uniformity, redispersibility, in-use stability, and caregiver dosing accuracy.

Does HETLIOZ have biosimilar risk?

No. Tasimelteon is a small-molecule drug, not a biologic. Competitive products would follow the generic drug or 505(b)(2) pathways rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2014). HETLIOZ (tasimelteon) capsules, prescribing information.
2. U.S. Food and Drug Administration. (2020). HETLIOZ LQ (tasimelteon) oral suspension, prescribing information.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2019). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.
5. Vanda Pharmaceuticals, Inc. (2023). Annual report on Form 10-K.
6. U.S. Food and Drug Administration. (2022). Product-specific guidances for generic drug development.